Back to top
more

InflaRx (IFRX)

(Delayed Data from NSDQ)

$1.36 USD

1.36
71,453

0.00 (0.00%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $1.35 -0.01 (-0.74%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IFRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

InflaRx N.V. [IFRX]

Reports for Purchase

Showing records 1 - 20 ( 51 total )

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 1

03/22/2024

Company Report

Pages: 8

4Q23 Results; INF904 Development Plans Focused on Chronic Inflammatory Skin Conditions

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 2

01/25/2024

Company Report

Pages: 6

InflaRx Announces Launch of Commitment Program for Gohibic; Lowering PT Due to Lower Revenue Expectations

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 3

01/05/2024

Company Report

Pages: 7

Encouraging Topline Results From MAD Part of Phase 1 Study of INF904

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 4

11/06/2023

Daily Note

Pages: 3

First Patient Dosed in Phase 3 PG Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 5

11/02/2023

Company Report

Pages: 8

3Q23 Results; Gohibic Records First Commercial Sales

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 6

09/12/2023

Company Report

Pages: 7

Positive Results From Phase 1 Single Ascending Dose Study of INF904

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 7

08/30/2023

Daily Note

Pages: 3

MAA for Gohibic (vilobelimab) in COVID-19 Validated and Under Review

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 8

08/11/2023

Company Report

Pages: 8

2Q23 Results; Gohibic in COVID-19 U.S. Commercial Launch Ongoing; cSCC Data Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 9

06/21/2023

Daily Note

Pages: 3

U.S. Commercial Launch of Gohibic for Critically Ill COVID-19 Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 10

05/12/2023

Company Report

Pages: 8

1Q23 Results; First Gohibic Sales Expected 3Q23; Phase 3 Study in PG Anticipated to Start Mid-Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 11

04/21/2023

Company Report

Pages: 7

Model Update Following Capital Raise; Lowering PT by $1 Due to Dilution

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 12

04/05/2023

Company Report

Pages: 7

FDA Grants Emergency Use Authorization For Gohibic (vilobelimab) For the Treatment of Critically Ill COVID-19 Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 13

03/23/2023

Company Report

Pages: 8

4Q22 Results; PG Phase 3 Trial to Enroll First Patient in Mid-23; Still Waiting for Potential EUA for COVID-19 Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 14

01/05/2023

Company Report

Pages: 8

Update on Phase 3 Trial of Vilobelimab in Pyoderma Gangrenosum

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 15

12/22/2022

Company Report

Pages: 7

Amended Co-Development Agreement With STS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 16

11/10/2022

Company Report

Pages: 8

3Q22 Results; Vilobelimab for COVID-19 EUA Request Submitted to FDA in September, Awaiting a Response

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 17

09/29/2022

Daily Note

Pages: 3

Emergency Use Authorization Request For Vilobelimab For the Treatment of Critically Ill COVID-19 Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 18

08/08/2022

Company Report

Pages: 6

2Q22 Results; Application for EUA for Vilobelimab in COVID-19 Expected This Quarter; Raising PT by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 19

07/26/2022

Daily Note

Pages: 3

Plans for FDA Emergency Use Authorization Application For Vilobelimab in COVID-19 Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: InflaRx N.V.

Industry: Medical - Biomedical and Genetics

Record: 20

07/06/2022

Daily Note

Pages: 3

Fast Track Designation Granted to Vilobelimab in Ulcerative Pyoderma Gangrenosum

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party